SandboxAQ brings its drug discovery models to Claude

SandboxAQ has built its drug discovery models into Claude, making advanced biocomputational tools available to researchers without specialized computer science training.

Access over quality

While competitors such as Chai Discovery and Isomorphic Labs race to improve the models themselves, SandboxAQ is betting on something else: the main barrier to adopting AI in drug development is not a shortage of quality but the lack of a simple interface for the target audience. The models are already powerful enough. But they are owned mostly by large companies with their own teams of data scientists. Meanwhile, most biochemists and molecular biologists have never written code. The Claude integration closes exactly this gap.

How it works

A researcher opens Claude and asks a question in plain language: "Give recommendations for optimizing this compound," "Predict the activity of the molecule in this context," "What analogs exist in the literature." SandboxAQ's models process the request, analyze the molecular structures and return a result. No code, no parsing of formats. The biologist stays in a familiar environment but gains access to tools that previously required a computer scientist's expertise.

Competition in AI for life sciences

Several players are already active in the drug discovery tools market:

• Chai Discovery — builds models for molecular design and property prediction
• Isomorphic Labs (a DeepMind subsidiary) — focuses on predicting 3D protein structures
• SandboxAQ — embeds tools in popular platforms such as Claude

Each has chosen its own path, but all agree that AI dramatically cuts the time and cost of developing molecules. What used to take years is now a matter of months.

What this means

The integration shows that AI for life sciences is moving out of the lab and into mass-market products. Building capabilities into familiar interfaces is sometimes more effective than refining the algorithms themselves. This may speed up drug development at small companies and universities that have no machine learning departments of their own.